Block Grant R36CK000103

This $2,026,211 Cooperative Agreement award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, aims to evaluate the feasibility and patient acceptance of remote self-sampling approaches for screening and monitoring HPV-related oropharyngeal cancer. The award will fund a prospective cohort study of 100 oropharyngeal cancer patients and 1,100 individuals from the general population aged 45-69. The study...

This $643,363 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support a hybrid type III effectiveness-implementation trial to test best practices for deploying a screen and treat approach to cervical cancer screening utilizing self-collected HPV DNA testing within HIV care and treatment facilities in Mozambique. The primary outcome is the number of women screened and screen-positive women receiving...

This Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $511,959 to Baylor University to conduct a hybrid type 2 effectiveness-implementation trial of the HOPE intervention. The HOPE intervention combines HPV self-sampling with a 3R communication model to promote cervical cancer screening among women living with HIV in Ghana. The project aims to develop an evidence-based implementation plan and provider training content...

This federal Cooperative Agreement award of $585,943 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop a low-cost, rapid, and easy-to-use point-of-care HPV DNA test to improve cervical cancer screening in Mozambique. Key objectives include: Adapting existing extraction-free, multiplexed, isothermal HPV DNA amplification assays to the NATFLOW platform for an integrated nucleic acid amplification and lateral flow detection...

The National Cancer Institute (NCI) awarded a $630,506 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Johns Hopkins University to develop therapeutic HPV vaccines that are highly effective against cervical cancers associated with diverse HPV16 variants. The primary goals are to: 1) characterize immune evasion by HPV16 variant epitopes, 2) evaluate growth and tumor microenvironment of spontaneous HPV-driven cervical carcinoma models, and 3) assess the efficacy of a novel HPV DNA...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $164,000 to the University of California, San Francisco to conduct a pilot study evaluating the feasibility and acceptability of using mail-delivered sample collection kits to test for oral HPV infection among people living with HIV. The study aims to assess the agreement between at-home self-collected samples and...

This federal Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,114,893 to Teal Health Inc. to conduct a clinical study evaluating the Teal self-collect device for primary HPV screening in cervical cancer detection. The key objectives are to confirm the usability of the Teal self-collect device and evaluate its agreement with clinician-collected samples for detecting high-risk HPV, with the aim of supporting Teal Health's...

The National Cancer Institute (NCI) awarded a Cooperative Agreement of $705,051 to the University of Washington on May 15, 2024 under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The purpose of this award is to adapt and evaluate two programs to integrate human papillomavirus (HPV) self-sampling into federally qualified health centers (FQHCs) in order to increase cervical cancer screening rates in priority populations. The project will conduct a two-phase...

This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program. The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data...

This federal Project Grant award of $723,513 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports the development, testing, and dissemination of the "Personalized Risk-Based Follow-Up of Cervical Cancer Screening in Practice" (PREDICT) intervention. The PREDICT program aims to address barriers to implementing personalized, risk-based cervical cancer screening and management guidelines by developing a health IT-enabled, multi-level...